Lumakras is a prescription medicine used to treat adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery and who have received at least one prior systemic therapy.
Sotorasib
Generic Name/API:Sotorasib
Packaging:Bottle of 240 tablets
Storage:Store at 20°C to 25°C
Dosage:For dosage information, please check the General Information section.
Strength:120 mg tablet
Indication:Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. KRAS G12C-mutated NSCLC is a form of non-small cell lung cancer characterized by a specific mutation—G12C—in the KRAS gene, which regulates cell growth and division. This mutation is found in about 11–15% of NSCLC cases and represents a key oncogenic driver. The G12C variant is especially important because it is now targetable with specialized therapies, offering new treatment options for affected patients.
Lumakras (sotorasib) is the first FDA-approved therapy designed to target the KRAS G12C mutation, a previously untreatable driver of cancer. By selectively inhibiting the mutant KRAS protein, Lumakras disrupts cancer cell growth while sparing healthy cells. Approved for non-small cell lung cancer (NSCLC) affecting about 13% of patients with this mutation, it offers a convenient once-daily oral option over traditional therapies. Ongoing trials in other cancers like colorectal and pancreatic highlight its potential to become a cornerstone in precision oncology.
STRENGTH: 120 mg tablet
DOSAGE:
The recommended dosage of lumakras is as follows
960 mg (eight 120 mg tablets) orally once a day until disease progression or unacceptable toxicity.
Dosage modification for adverse reactions: If adverse reactions arise, up to two dose reductions are allowed. LUMAKRAS should be discontinued if the patient cannot tolerate the minimum dose of 240 mg once daily.
| Dose reduction level | Dose |
| First dose reduction | 480mg (4 tablets) once daily |
| Second dose reduction | 240mg (2 tablets) once daily |
ADVERSE REACTION: The following are the adverse reaction of Lumakras:
- Hepatotoxicity
- Pneumonia
- Musculoskeletal pain
STORAGE: Store Lumakras tablets at 20°C to 25°C, can exceed from 15°C to 30°C.
Hepatotoxicity: LUMAKRAS may cause hepatotoxicity, leading to liver injury or hepatitis. In the CodeBreaK 100 trial (n=357), 1.7% of patients experienced hepatotoxicity (1.4% Grade 3), and 18% had elevated ALT/AST levels, with 6% at Grade 3 and 0.6% at Grade 4. The median onset was 9 weeks. Dose adjustments were required in 7% of cases, and 2% discontinued treatment. Corticosteroids were used in 5% of patients to manage liver enzyme elevations.
Interstitial Lung Disease (ILD)/Pneumonitis: LUMAKRAS may cause fatal ILD/pneumonitis. In the CodeBreaK 100 trial, it occurred in 0.8% of patients (all Grade 3/4), with one fatality and 0.6% discontinuation. Median onset was 2 weeks. Monitor for cough, dyspnea, or fever. Withhold treatment if suspected and permanently discontinue if no other cause is found.
FAQ
How is Lumakras taken?
Lumakras is taken orally, once daily, with or without food, as a tablet. It should be taken at the same time each day.
Who is eligible for Lumakras?
Adults with locally advanced or metastatic NSCLC who test positive for the KRAS G12C mutation and have already received at least one systemic treatment (like chemotherapy or immunotherapy).
Is genetic testing required before starting Lumakras?
Yes. Patients must have a confirmed KRAS G12C mutation via an FDA-approved test before starting treatment.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) and possess valid operating license. These credentials confirm that the supplier’s adherence to International standards for the proper distribution of medicinal products.
What is the cost of Lumakras (Sotorasib) in India?
The cost of Lumakras (Sotorasib) tablets varies as it’s not approved in India and must be imported. Factors like international currency exchange rates (USD/EUR), import duties, and supplier availability influence the final price. For the latest pricing and details, please contact 247 QualityMeds.
How to buy Lumakras (Sotorasib) online in India?
To buy Lumakras (Sotorasib) tablets in India at a genuine price, contact 24/7 QualityMeds. We assist you in importing this medication legally and at the best possible price.
